ADC Therapeutics specialized in the development of proprietary antibody drug conjugates and Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, agreed upon a exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers. ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to it’s portfolio of proprietary ADC programs. These unique platforms combines monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based “warheads”. Because these PBD-based chemistries do not distort the structure of the DNA they offer the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.

Advertisement #4